Moreover, the administration of EGFR inhibitors inhibits acetylcholine-induced ERK1/2 kinase phosphorylation, which is reflected in a significant decrease in colon cancer cell proliferation. The gene discussed is MAPK3; the disease is colonic neoplasm.